FNCH Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States...

Stats
Today's Volume	117 233
Average Volume	39 864.00
Market Cap	3.69M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0.0420 (1.83%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Smisek Jeffery A	Sell	1 600	Common Stock
2024-03-28	Smisek Jeffery A	Sell	6 642	Common Stock
2023-11-22	Smisek Jeffery A	Sell	1 470	Common Stock
2023-06-09	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)
2023-06-08	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)

INSIDER POWER
97.84
Last 84 transactions
Buy: 22 938 760 \| Sell: 28 923 806

Volume Correlation

Long: 0.20 (neutral)

Short: -0.60 (weak negative)

Signal:(41.778) Neutral

Finch Therapeutics Group, Correlation

10 Most Positive Correlations
ACET	0.917
VNDA	0.917
AFMD	0.914
COMT	0.91
GROM	0.903
STRC	0.889
EQRX	0.889
AYLA	0.883
ADSE	0.882
TRVN	0.874

10 Most Negative Correlations
IDLB	-0.867
ISDX	-0.855
EVOP	-0.839
QADA	-0.815
LMRK	-0.812
ISEM	-0.811

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Finch Therapeutics Group, Correlation - Currency/Commodity

0.73
( moderate )

0.62
( weak )

0.00
( neutral )

-0.46
( neutral )

0.51
( weak )

-0.84
( strong negative )

Finch Therapeutics Group, Financials

Annual	2023
Revenue:	$107 000
Gross Profit:	$-1.41M (-1 320.56 %)
EPS:	$-46.59

Q4	2023
Revenue:	$0
Gross Profit:	$-44 000.00 (0.00 %)
EPS:	$-1.890

Q3	2023
Revenue:	$0
Gross Profit:	$-52 000.00 (0.00 %)
EPS:	$-1.510

Q2	2023
Revenue:	$0
Gross Profit:	$-57 000.00 (0.00 %)
EPS:	$-4.33

Financial Reports:

No articles found.

Finch Therapeutics Group,

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.